Stocks · News reference
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $21.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Tandem Expands Mobi Availability To 12 International Markets, Pairing Control-IQ+ Predictive Algorithm, Studied In Type 1, Pregnancy And Type 2 Diabetes, With Dexcom G7 Sensor
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Tandem Diabetes (TNDM) is positioned for growth with its expanding product roadmap including the Mobi tubeless pump, new CGM integrations, and AIDANET closed-loop program. The company's pay-as-you-go reimbursement model aims to lower upfront barriers and boost recurring supply revenue. However, macroeconomic pressures, reimbursement sensitivity, competitive threats, and the impact of GLP-1 drugs on insulin therapy demand pose significant headwinds to sustained profitability.